Clinical observation of high-dose glucocorticoid shock therapy on patients with unilateral total deafness with sudden sensorineural hearing loss
Objective To explore the clinical efficacy and safety of high-dose glucocorticoid shock therapy in patients with unilateral total deafness with sudden sensorineural hearing loss(SSNHL).Methods A total of 52 patients with unilateral total deafness with SSNHL in Affiliated Hospital of Inner Mongolia Medical University from August 2020 to August 2022 were were selected,and randomly divided into treatment group and control group,with 26 cases in each group.The control group was treated with routine glucocorticoid therapy,while the treatment group was treated with high-dose glucocorticoid shock therapy.The hearing improvement effect and adverse reactions of the two groups were compared.Results Among the 52 patients,there were 20 males and 32 females,aged from 22 to 65 years old,with an average of(45.4±11.3)years old.The average hearing threshold of the two groups after treatment was lower than that before treatment,and that of the treatment group was lower than that of the control group.The total effective rate in the treatment group was higher than that in the control group(80.77%vs.53.85%),and the incidence of adverse reactions in the treatment group was higher than that in the control group(61.54%vs.19.23%),and the differences were statistically significant(P<0.05).Conclusions The high-dose glucocorticoid shock therapy can effectively improve the hearing of patients with unilateral total deafness,but the incidence of adverse reactions during treatment is high.
sudden sensorineural hearing loss(SSNHL)unilateral total deafnessglucocorticoidhigh-doseshock therapyclinical efficacy
NETL
NSTL
万方数据
